Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the primary outcome of the CAR-T cell therapy for the 15-year-old with lupus by end of 2024?
Complete remission • 25%
Partial remission • 25%
No change • 25%
Worsening condition • 25%
Medical reports and publications from Universitätsklinikum Erlangen or updates in The Lancet
First CAR-T Cell Therapy for 15-Year-Old with Lupus in Germany Shows Promising Results
Jul 11, 2024, 02:36 PM
The world's first CAR-T cell therapy for a child with lupus has shown promising results. A 15-year-old teen from Universitätsklinikum Erlangen in Germany received the treatment in 2023 and reported feeling as good as before the diagnosis, with only a few colds. Previously, CAR-T cells had been used primarily for leukemia, lymphoma, and in studies on adults with advanced autoimmune diseases. This marks the first time the therapy has been used for treating children with autoimmune conditions. The findings were published in a new paper in The Lancet. The breakthrough was highlighted by NatureBiotech and acknowledged by BertrandBio.
View original story
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No major side effects • 25%
Increased survival rate • 25%
Reduced secondary cancer rate • 25%
Improved quality of life • 25%
Other • 25%
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Improved survival rates • 25%
Increased cancer rates • 25%
Stable condition • 25%
Other • 25%
Cytokine release syndrome (CRS) • 25%
Immune effector cell-associated neurotoxicity syndrome (ICANS) • 25%
Secondary cancers • 25%
Other • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
0-5 • 25%
21+ • 25%
11-20 • 25%
6-10 • 25%